Faculty profile

Anna Blakney

ResearcherMichael Smith LaboratoriesUniversity of British Columbia

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.

Anna Blakney

Researcher

Michael Smith Laboratories

Health Sciences

University of British Columbia

Vancouver, British Columbia, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
1 publication in the last five years, latest in 2026.
Principal investigator on 11 research grants (9 CIHR, 2 NSERC), most recently in 2026.
Supervised 1 trainee who won CIHR awards, most recently in 2023.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Lipid Nanoparticles Self-Amplifying Rna Immunogenicity Humoral Immunity Messenger Rna Nanomedicine Rna Animal Models

Latest papers

Advancing regenerative medicine with RNA nanotechnology for chronic and end organ diseases.
Communications medicine · 2026

All 1 publications

Latest funding

A Platform RNA Vaccine Strategy for Disease X Using Tetraspanin-Displayed Epitopes
CIHR · 2026 · Nominated PI
$300,000
Engineering Longer-Lasting RNA Therapeutics for Treatment of Blood Disorders
CIHR · 2025 · Nominated PI
$879,750
Development and evaluation of novel nanoparticle formulations for therapeutic genome editing
CIHR · 2023 · Principal investigator
$975,376

All 13 grants and awards

A Platform RNA Vaccine Strategy for Disease X Using Tetraspanin-Displayed Epitopes

Nominated PICIHR2026Operating Grant: Leadership Award for Vaccine Res. - CEPI-CIHR

Principal investigators: Blakney, Anna

Keywords: Disease X; Immunoengineering; Immunogenicity; Lipid Nanoparticles; Mrna Vaccine; Nanomedicine; Nipah Virus; Rift Valley Fever Virus; Self-Amplifying Rna; Tetraspanin

$300,000

Engineering Longer-Lasting RNA Therapeutics for Treatment of Blood Disorders

Nominated PICIHR2025Project Grant

Principal investigators: Blakney, Anna

Keywords: Blood Disorders; Drug Delivery; Factor Vii Deficiency; Gene Therapy; Immunogenicity; Lipid Nanoparticles; Rna Therapeutics; Self-Amplifying Rna

$879,750

Development and evaluation of novel nanoparticle formulations for therapeutic genome editing

Principal investigatorCIHR2023Project Grant

Principal investigators: Ross, Colin J; Blakney, Anna

Keywords: Animal Models; Base Editor; Gene Editing; Genetic Disease; Lipid Nanoparticle; Nanoparticle; Prime Editor

$975,376

Expanding the repertoire of highly efficient self-amplifying ribonucleic acid vectors for next-generation vaccines.

SupervisorCIHR2023Doctoral Research Award: Canada Graduate Scholarships

Principal investigators: Casmil, Irafasha Credo

Keywords: Delivery Systems; Ex Vivo; Immunity; In Vivo; Messenger Rna; Nucleic Acids; Self-Amplifying Rna; Vaccines; Vector Development; Virology

$105,000

Engineering next-generation self-amplifying RNA therapeutics encoding bispecific T cell engager (BiTE) antibodies for treatment of ovarian cancer

Nominated PICIHR2023Project Grant

Principal investigators: Blakney, Anna

Keywords: Bispecific T Cell Engager; Formulation; Innate Immunity; Lipid Nanoparticles; Monoclonal Antibody; Ovarian Cancer; Pharmacokinetics; Protein Expression; Rna; Self-Amplifying Rna

$795,600

A development platform for mutation-resistant vaccines and antibodies for SARS-CoV-2 future variants

Co-investigatorCIHR2022Project Grant - PA: Pandemic Preparedness and Health Emergencies Research

Principal investigators: Plotkin, Steven S

Keywords: Deep Mutational Scanning; Genomics; Mutational Escape; Pseudotyped Viruses; Rationally Designed Antibodies; Rationally Designed Vaccines; Sars-Cov-2 Spike Protein; Structural Biology; Viral Evolution

$100,000

Optimization of next-generation RNA vaccines for pandemic preparedness

Nominated PICIHR2022Project Grant - PA: Pandemic Preparedness and Health Emergencies Research

Principal investigators: Blakney, Anna

Keywords: Humoral Immunity; Lipid Nanoparticles; Messenger Rna; Nanomedicine; Pandemic Preparedness; Polyethylene Glycol; Reactogenicity; Rna; Self-Amplifying Rna; Vaccines

$100,000

Development and evaluation of novel nanoparticle formulations for therapeutic genome editing

Principal investigatorCIHR2022Project Grant

Principal investigators: Ross, Colin J; Blakney, Anna

Keywords: Animal Models; Base Editor; Gene Editing; Genetic Disease; Lipid Nanoparticle; Nanoparticle; Prime Editor

$100,000

Canada Research Chairs - Tier 2

Nominated PICIHR2022Canada Research Chairs - CIHR Funded - Tier 2

Principal investigators: Blakney, Anna

Keywords: Crc

$600,000

Mechanisms of immunity and protection against Chlamydia of RNA and protein vaccines

Nominated PICIHR2021Catalyst Grant: STBBI Research in Canada: Beyond HIV/AIDS/Hepatitis C - General

Principal investigators: Blakney, Anna

Keywords: Cellular Immunity; Challenge Model; Chlamydia; Humoral Immunity; Immunogenicity; Lipid Nanoparticles; Messenger Rna; Recombinant Protein; Self-Amplifying Rna; Vaccine

$100,000

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Something wrong or missing on this profile? Suggest a correction

Anna Blakney

Research

Latest papers

Latest funding

Advancing regenerative medicine with RNA nanotechnology for chronic and end organ diseases.

A Platform RNA Vaccine Strategy for Disease X Using Tetraspanin-Displayed Epitopes

Engineering Longer-Lasting RNA Therapeutics for Treatment of Blood Disorders

Development and evaluation of novel nanoparticle formulations for therapeutic genome editing

Expanding the repertoire of highly efficient self-amplifying ribonucleic acid vectors for next-generation vaccines.

Engineering next-generation self-amplifying RNA therapeutics encoding bispecific T cell engager (BiTE) antibodies for treatment of ovarian cancer

A development platform for mutation-resistant vaccines and antibodies for SARS-CoV-2 future variants

Optimization of next-generation RNA vaccines for pandemic preparedness

Development and evaluation of novel nanoparticle formulations for therapeutic genome editing

Canada Research Chairs - Tier 2

Mechanisms of immunity and protection against Chlamydia of RNA and protein vaccines

Frequent collaborators

Bowen Li

Gang Zheng

Michael Sefton

Mamatha Bhat

Sarah Hedtrich